# China NMPA Drug Inspection - Guiyang Daosheng Health Industry Co., Ltd. - Acanthopanax senticosus

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guiyang-daosheng-health-industry-co-ltd/d6b60424-41af-4e19-a946-c874aa5b4f37/
Source feed: China

> China NMPA drug inspection for Guiyang Daosheng Health Industry Co., Ltd. published December 22, 2020. Drug: Acanthopanax senticosus. On December 22, 2020, the Guizhou Provincial Drug Administration released its third drug quality announcement of the yea

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Guizhou Provincial Drug Administration Drug Quality Bulletin (Drug Sampling Inspection Information Announcement) (Issue 3, 2020) (Total Issue 41)
- Company Name: Guiyang Daosheng Health Industry Co., Ltd.
- Publication Date: 2020-12-22
- Drug Name: Acanthopanax senticosus
- Inspection Finding: The product does not meet the requirements; the non-compliant item is leachate.
- Action Taken: Drug regulatory authorities at all levels will investigate and prosecute cases in accordance with relevant laws and regulations, strengthen supervision, urge offenders to correct illegal activities, and enhance risk prevention and control.
- Summary: On December 22, 2020, the Guizhou Provincial Drug Administration released its third drug quality announcement of the year (Issue 41), identifying quality failures in 10 batches of drugs from eight different manufacturers. The inspections, conducted under the Drug Administration Law of the People's Republic of China and related sampling measures, targeted producers, distributors, and healthcare facilities to ensure public safety.

The non-compliant companies included Guiyang Daosheng Health Industry, Guizhou Jingfeng Injection, Anhui Zehua, Jilin Aodong Taonan Pharmaceutical, Sichuan Gukang, Hunan Honghua, Zhangshu Rende, and Sichuan Yifang. Key violations involved failures to meet chemical standards for active ingredients (such as glycyrrhizin and osthol), excessive moisture levels, rancidity, and issues with extract purity and physical appearance. Notably, some samples raised concerns regarding product authenticity, with one manufacturer denying production of the tested batch.

The regulatory framework cited for these actions includes the Administrative Measures for Drug Quality Sampling Inspection. Following these findings, the Administration has ordered local regulatory departments to investigate and prosecute the responsible parties. The involved companies must correct their illegal activities and implement enhanced risk prevention measures to prevent future quality deviations.

Company: https://www.globalkeysolutions.net/companies/guiyang-daosheng-health-industry-co-ltd/ba1f1eb0-3dd9-452d-af1c-1abebf6bb8eb/